Andrew Hollman Meyer Sells 50,000 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) Stock

Janux Therapeutics, Inc. (NASDAQ:JANX) insider Andrew Hollman Meyer sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total transaction of $2,298,000.00. Following the transaction, the insider now directly owns 67,592 shares in the company, valued at $3,106,528.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Janux Therapeutics Price Performance

NASDAQ:JANX opened at $46.25 on Friday. Janux Therapeutics, Inc. has a 1 year low of $5.65 and a 1 year high of $65.60. The stock’s 50 day simple moving average is $43.92 and its two-hundred day simple moving average is $44.56. The company has a market cap of $2.40 billion, a price-to-earnings ratio of -37.91 and a beta of 3.57.

Janux Therapeutics (NASDAQ:JANX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. Janux Therapeutics’s quarterly revenue was up 709.1% compared to the same quarter last year. As a group, analysts anticipate that Janux Therapeutics, Inc. will post -1.18 EPS for the current year.

Institutional Investors Weigh In On Janux Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Swiss National Bank raised its stake in Janux Therapeutics by 39.5% in the fourth quarter. Swiss National Bank now owns 31,800 shares of the company’s stock worth $341,000 after buying an additional 9,000 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at $553,000. China Universal Asset Management Co. Ltd. boosted its holdings in Janux Therapeutics by 82.4% in the first quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock worth $367,000 after acquiring an additional 4,400 shares in the last quarter. Capstone Investment Advisors LLC acquired a new position in Janux Therapeutics during the 1st quarter valued at approximately $1,969,000. Finally, Lester Murray Antman dba SimplyRich purchased a new stake in shares of Janux Therapeutics during the first quarter valued at $300,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

JANX has been the topic of several research reports. Wedbush restated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a report on Thursday, August 8th. Stifel Nicolaus began coverage on Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating and set a $100.00 price objective on shares of Janux Therapeutics in a report on Monday, September 16th. Scotiabank lowered their price objective on shares of Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating on the stock in a report on Friday, August 9th. Finally, HC Wainwright restated a “buy” rating and set a $63.00 target price on shares of Janux Therapeutics in a research report on Monday, August 19th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $66.13.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.